This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Alberta directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $975,376
Targeting MAEA to Overcome PARP Inhibitor Resistance in High-Grade Serous Ovarian Cancer: Mechanisms and Therapeutic Strategies
CIHR · 2026 · Nominated PI
- $940,950
Polynucleotide kinase/phosphatase: its role in DNA strand break repair and a potential therapeutic target to enhance radio- and chemotherapy
CIHR · 2019 · Co-investigator
- $60,000
Targeting DNA Repair Pathways for Multiple Myeloma Treatment
CIHR · 2017 · Nominated PI
Targeting MAEA to Overcome PARP Inhibitor Resistance in High-Grade Serous Ovarian Cancer: Mechanisms and Therapeutic Strategies
Principal investigators: Ismail, Ismail H
Keywords: Dna Double-Strand Break Repair; E3 Ubiquitin Ligase, Maea; Homologous Recombination; Parp Inhibitor; Replication Fork
Polynucleotide kinase/phosphatase: its role in DNA strand break repair and a potential therapeutic target to enhance radio- and chemotherapy
Principal investigators: Weinfeld, Michael
Keywords: Dna Repair; Synthetic Lethality
Targeting DNA Repair Pathways for Multiple Myeloma Treatment
Principal investigators: Ismail, Ismail H
Keywords: Crs
The role of small ubiquitin-like modifier (SUMO) in DNA end resection
Principal investigators: Ismail, Ismail
The regulation of homologous recombination by RNF138
Principal investigators: Ismail, Ismail H
Keywords: Ctip; Dna Double-Strand Breaks; Dna End Resection; Dna Repair; Dna Repair Foci; Genomic Instability; Mrn; Rnf138; Rpa; Ubiquitylation
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.